Our data indicated that higher Mig6 expression was strongly associated with lower levels of EGFR phosphorylation and erlotinib resistance in 6 of 6 head and neck and prostate cancer cell lines assayed (Figure 3A and B). The gene discussed is EGFR; the disease is prostate cancer.